Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

Pere Barba, Izaskun Elorza

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

© 2019 Elsevier España, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.
Original languageEnglish
Pages (from-to)28-34
JournalMedicina Clinica
Volume153
Issue number1
DOIs
Publication statusPublished - 5 Jul 2019

Keywords

  • Acute lymphoblastic leukaemia
  • Allogeneic transplantation
  • CAR-T
  • Immunotherapy
  • Monoclonal antibodies

Fingerprint Dive into the research topics of 'Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia'. Together they form a unique fingerprint.

Cite this